Table 2.
Characteristics of the study group according to albuminuria status and group-specific median cC-GFRa
| Variable | Normoalbuminuria | Microalbuminuria | Group Contrast | |||
|---|---|---|---|---|---|---|
| Characteristic | cC-GFR > 115 | cC-GFR < 115 | cC-GFR > 101 | cC-GFR < 101 | AER | cC-GFR |
| N | 183 | 180 | 152 | 152 | Pb | Pc |
| AER (μg/min) | 13 (10-18) | 18 (12-23) | 56 (42-100) | 85 (51-161) | By Design | <0.0001 |
| Age (yr) | 37 ± 11 | 40 ± 13 | 36 ± 12 | 45 ± 11 | <0.05 | <0.0001d |
| Diabetes duration (yr) | 19 ± 9 | 21 ± 10 | 20 ± 9 | 26 ± 9 | <0.0001 | <0.0001d |
| HbA1c (%) | 8.3 ± 1.2 | 8.3 ± 1.2 | 8.7 ± 1.6 | 8.4 ± 1.4 | <0.005 | NS |
| Body mass index (kg/m2) | 25.6 ± 3.6 | 26.7 ± 4.3 | 27.2 ± 4.8 | 27.7 ± 5.2 | <0.0005 | <0.05 |
| Systolic blood pressure (mmHg) | 118 ± 12 | 120 ± 13 | 124 ± 12 | 125 ± 15 | <0.0001 | NS |
| ACEI or ARB Rx (%)d | 18% | 21% | 49% | 55% | <0.0001 | NS |
| Antihypertensive Rx (%) | 7% | 16% | 14% | 30% | <0.001 | <0.0001 |
| Serum cholesterol (mg/dl) | 183 ± 29 | 181 ± 29 | 190 ± 33 | 193 ± 30 | <0.0001 | NS |
| Lipid-lowering Rx (%) | 24% | 34% | 31% | 42% | <0.05 | <0.005 |
| Current smoker (%) | 9% | 12% | 19% | 18% | <0.005 | NS |
a
Data are mean ± SD, median (quartiles), or %.
b
P-value for the albuminuria main effect in an ANOVA
c
P-value for the cC-GFR main effect in an ANOVA.
d
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; Rx, treatment.